Odonate Therapeutics, Inc. (ODT)
Odonate Therapeutics, Inc. operates in the Biotechnology industry of the Healthcare sector, headquartered in San Diego, CA, US. The stock last traded at $1.12, down 4.27% on the session, giving a market capitalisation of $0. On trailing twelve-month figures it carries a trailing P/E of 3227.62, a net margin of 0.0%. Its beta of 0.45 implies it has historically moved less than the broad market.
Odonate Therapeutics, Inc. functions as a pharmaceutical enterprise, dedicating its efforts to the creation of innovative therapeutic agents for cancer treatment. A prominent compound within its development pipeline is tesetaxel, an orally administered chemotherapy drug. This agent is currently advancing through Phase III clinical trials, specifically under investigation for its application in individuals with metastatic breast cancer. Established in 2013, the company's operations are headquartered in New York, New York.
Odonate Therapeutics, Inc. is most often compared with the following Healthcare names: